|Min SIP Amount||Not Supported|
|NAV||₹10.98 (05 Aug 2019)|
|Fund Started||29 Jul 2016|
|Fund Size||₹27 Cr|
|UTI Liquid Cash Direct-Growth||Financial||Mutual Fund||55.3%|
|L&T Fincorp Ltd.||Financial||Debenture||9.2%|
|L&T Housing Finance Ltd.||Financial||Debenture||9.2%|
|UTI Ultra Short Term Fund Direct-Growth||Financial||Mutual Fund||8.2%|
|HDFC Bank Ltd.||Financial||Equity||1.8%|
|NIIT Technologies Ltd.||Technology||Equity||1.2%|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||0.7%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||0.5%|
|CARE Ratings Ltd.||Financial||Equity||0.3%|
|Gateway Distriparks Ltd.||Services||Equity||0.1%|
UTI Dual Advantage Fixed Term Fund Series III III (1102 Days) Direct Growth is a Hybrid Mutual Fund Scheme launched by UTI Mutual Fund. This scheme was made available to investors on 29 Jul 2016. V Srivatsa, Sunil Patil is the Current Fund Manager of UTI Dual Advantage Fixed Term Fund Series III III (1102 Days) Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹27 Cr and the Latest NAV as of 05 Aug 2019 is ₹10.98.
The UTI Dual Advantage Fixed Term Fund Series III III (1102 Days) Direct Growth is rated Moderately High risk.
The scheme seeks to generate income and reduce interest rate volatility by investing in fixed income securities that are maturing on or before the date of maturity of the Scheme and generate capital appreciation by investing in equity and equity related instruments.